Tracked deals
4
4 tracked deals across 2020-2024.
Franklin Lakes, New Jersey, United States
BD is one of the world's largest pure-play medical technology companies advancing the world of health through innovation across medical essentials, connected care, biopharma systems, and interventional; it develops and manufactures medical devices, diagnostics and healthcare delivery solutions.
Tracked deals
4
4 tracked deals across 2020-2024.
Recent pace
0
0 tracked deals announced in the last 12 months.
Deal mix
Buyout
3 buyout · 1 divestiture
Last 4 years
Supporting Data
BD (Becton, Dickinson and Company) completed the acquisition of Edwards Lifesciences' Critical Care product group and has renamed the business BD Advanced Patient Monitoring, based in Irvine, California. The deal expands BD's smart connected care portfolio with advanced monitoring technologies and AI-enabled clinical decision tools, and aligns the new unit within BD's Medical segment to enable integration with BD's infusion platforms and future closed-loop monitoring innovations.
BD (Becton, Dickinson and Company) has completed its acquisition of Parata Systems, a provider of pharmacy automation and medication management solutions. The deal brings Parata into BD's Medication Management Solutions business to expand BD's smart, connected care capabilities across retail, hospital and long-term care pharmacies.
Becton, Dickinson and Company (BD) has acquired Tepha, Inc., a developer and manufacturer of a proprietary resorbable polymer (P4HB) and the GalaFLEX product portfolio, to strengthen BD's surgical mesh offerings. The deal provides BD with vertical integration of a key supply-chain component for its Phasix Mesh products and supports capability expansion into soft tissue repair, reconstruction and regeneration; terms were not disclosed.
Becton Dickinson (BD) has acquired NAT Diagnostics, a molecular diagnostics firm that developed an isothermal NAT Dx technology for rapid point-of-care testing. BD plans to further develop the NAT Dx platform to offer decentralized molecular testing options targeted for early 2023, expanding BD’s capabilities in point-of-care molecular diagnostics.
Turn tracked acquisition activity into an outreach-ready buyer list.